Exelixis, Inc. (NASDAQ:EXEL – Get Rating) was the recipient of a large decrease in short interest in the month of April. As of April 30th, there was short interest totalling 6,100,000 shares, a decrease of 9.9% from the April 15th total of 6,770,000 shares. Based on an average daily trading volume, of 3,100,000 shares, the […]
Exelixis, Inc. (NASDAQ:EXEL – Get Rating) was the target of unusually large options trading on Tuesday. Stock investors purchased 2,454 call options on the stock. This is an increase of 111% compared to the typical daily volume of 1,163 call options. Analyst Upgrades and Downgrades A number of equities analysts recently commented on EXEL shares. […]
Meritage Portfolio Management raised its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Get Rating) by 164.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 424,235 shares of the biotechnology company’s stock after buying an additional 264,052 shares during the quarter. Meritage Portfolio […]
A number of research firms have changed their ratings and price targets for Exelixis (NASDAQ: EXEL): 4/14/2023 – Exelixis was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating. 4/12/2023 – Exelixis had its price target lowered by analysts at Morgan Stanley from $22.00 to $21.00. They now have an “equal […]
State of Michigan Retirement System grew its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL – Get Rating) by 1.2% in the fourth quarter, HoldingsChannel reports. The fund owned 82,116 shares of the biotechnology company’s stock after buying an additional 1,000 shares during the period. State of Michigan Retirement System’s holdings in Exelixis were worth $1,317,000 […]